Donation

Pomalyst® (pomalidomide) is a third-generation immunomodulatory drug, which can modify or regulate the functioning of the immune system.

Who is a candidate for Pomalyst?

Pomalyst plus dexamethasone (Pd) is indicated for patients with myeloma who have received at least two prior therapies including both Revlimid® (lenalidomide) and a proteasome inhibitor such as Velcade® (bortezomib), Kyprolis® (carfilzomib), or Ninlaro® (ixazomib), and have demonstrated disease progression on or within 60 days of completion of the last therapy.

Pomalyst in other regimens

In addition to therapy with Pd alone, Pomalyst is used in triplet regimens for previously treated myeloma, including in the following combination therapies:

  • Darzalex® (daratumumab) plus Pd [DPd]
  • Empliciti® (elotuzumab) plus Pd [EPd]
  • Velcade® (bortezomib) plus Pd [PVd]
  • Kyprolis® (carfilzomib) plus Pd [KPd]
  • Sarclisa® (isatuximab-irfc) plus Pd [SPd]
  • Ninlaro® (ixazomib) plus Pd [IPd]
  • Cytoxan® (cyclophosphamide) plus Pd [PCd]

How is Pomalyst taken?

Pomalyst is taken in capsule form by mouth on days 1–21 of repeated 28-day cycles until disease progression. Pomalyst should be taken at the same time of the day, with or without food. Swallow Pomalyst with water.

Special cautions with Pomalyst

  • Pomalyst is contraindicated in pregnancy. Female patients of reproductive potential and all male patients are required to complete a monthly phone survey.
  • Pomalyst is available only through the “Pomalyst REMS®” (Risk Evaluation and Mitigation Strategy) program. Patients must sign an agreement and comply with the requirements.
  • If you take Pd (with or without another drug), you will receive a risk assessment from your doctor to determine which anticoagulant therapy is appropriate for you to prevent a blood clot.
  • Smoking may reduce the efficacy of Pomalyst.

Possible side effects of Pomalyst

Possible side effects of Pomalyst include low blood cell counts, unusual tiredness or physical weakness, nausea, back pain, increased risk of blood clots, neuropathy, upper respiratory infection or pneumonia, constipation, diarrhea, fever, dizziness and confusion, and shortness of breath.

Tell your doctor about any side effects that bother you or that do not go away. Make sure you know how to get in touch with your doctor after office hours, on the weekend, and over a holiday.

 

Manufacturer’s website

POMALYST® (pomalidomide) is a thalidomide analogue indicated, in combination with dexamethasone, for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.

Celgene Patient Support

Your Specialist is committed to helping patients access POMALYST, no matter their insurance situation.

Clinical Trials

Pomalyst® (pomalidomide) clinical trials

Open clinical trials on clinicaltrials.gov.

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.